Graduated in Pharmacy and Biochemistry from the Federal University of Paraná, UFPR. Master's and Doctorate in Sciences from the Federal University of São Paulo - UNIFESP (Molecular Biology program). Doctorate from the Pasteur Institute and INSERM (France). Post-doctorate at the National Academy of Medicine of Buenos Aires (ANMBs) - Argentina. She is a PqC-VI scientific researcher at Instituto Butantan where she acts as: Director of the Center for Development and Innovation at Instituto Butantan, Director of CENTD: Center of Excellence in New Target Discovery-FAPESP / GSK / IBu. She is a Productivity Researcher at CNPq and Associate Researcher at CeTICS-FAPESP. She is an accredited professor in the Postgraduate courses: Molecular Biology at UNIFESP, Interunits in Biotechnology at USP and Postgraduate Studies in Toxinology at Instituto Butantan. She acts as a Titular Member of the Municipal Council of Science and Technology and Innovation of the City of São Paulo and is a member of the Brazilian Network of Pharmaceutical Innovation. She serves as an Ad Hoc reviewer for several scientific journals and Funding Agencies. She coordinates projects aimed at public-private interaction, with support from various development agencies. Experience in Biochemistry, with emphasis on the discovery of molecules that act on immunoinflammatory diseases, cell survival, hemostasis and tissue remodeling. She coordinates projects for the discovery and validation of molecular targets in different cell models. Coordinates projects for the implementation of infrastructure for the development of new drugs, such as laboratories with different levels of biosafety, multipurpose laboratories, specialized platforms for the discovery and validation of molecular targets and biorepositories. She works in training in entrepreneurship and innovation through open courses and disciplines in undergraduate and graduate programs. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| A place in the sun |
| Antitumor protein |
| Una proteína antitumoral |
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Pain is a worldwide problem. The identification and validation of targets affecting pain are critical for the development of more effective and safe interventions. Venoms are rich in bioactive compounds and can be valuable tools to explore new molecular targets. For pain studies, we characterized a model to evaluate the anti-nociceptive effect of compounds in human sensory-like neurons de…
CENTD's focus is to combine the expertise of researchers at the Butantan Institute (biochemistry, OMICS, molecular and cellular biology, pharmacology, genetics, bioinformatics, immunology, and in vitro and in vivo assays) with GSK's experience in the search and validation of new targets related to immune-inflammatory diseases, to enable the design and development of new therapeutic agents…
Conventional epifluorescence microscopy, often utilized to screen the distribution of cellular components by use of immunolabelling, is a classical technique extensively present in different areas of research. However, it suffers from an important disadvantage, namely out-of-focus blur. This effect is due to the excitation of an entire field of view, which activates emission in the whole …
(Only some records are available in English at this moment)
Neurodegenerative diseases (ND) result from the gradual and progressive loss of neural cells, leading to nervous system dysfunction. As the era of aging society is approaching, ever-increasing number of people are afflicted with ND. However, there are currently no effective drugs to cure these diseases. The continual failures in clinical trails of ND drugs that target the pathological hal…
The Center of Excellence in New Target Discovery (CENTD) is the result of a partnership between the Butantan Institute and the São Paulo Research Foundation (FAPESP) and the Pharmaceutical GlaxoSmithKline (GSK). It aims to identify and validate new molecular targets and signaling pathways involved in inflammatory diseases. For the identification of these molecular targets, animal venoms, …
The equipment will be used for the discovery of new molecular targets involved in inflammatory diseases, using animal venoms and toxins as tools for the study of these diseases. This equipment allows fluorescence intensity quantification in suspension cells, as any other flow cytometer. However, differently from other flow cytometers, it provides images of cells analyzed, since it is equi…
(Only some records are available in English at this moment)
This project is about validation of molecular targets obtained in cellular models of inflammation subjected to various stimuli and further treated with anti-inflammatory synthetic peptides. The targets are identified by chemoproteomic and mass spectrometry strategies. The Postdoc fellow will focus primarily on validating the identified targets with the use of techniques of knockdown and o…
CENTD has been focusing on the study of new inflammatory targets as well as on the screening for anti-inflammatory compounds from our library of peptides derived from venoms. Our group recently identified potential venom-derived peptides with anti-inflammatory activity in established cell models for screening. In order to identify the molecular targets of these peptides in cell models, a …
The aim of the CENTD project is to use animal venoms, secretions and venom-derived peptides as tools to identify and validate new molecular targets and signaling pathways of immunoinflammatory-related diseases to be useful for the discovery of new therapies and new drug development. For this purpose, our center has implemented and characterized distinct cellular models of inflammation (ch…
The Center of Excellence in New Target Discovery (CENTD) is the result of a partnership between the Butantan Institute and the São Paulo Research Foundation (FAPESP) and the Pharmaceutical GlaxoSmithKline (GSK). It aims to identify and validate new molecular targets and signaling pathways involved in inflammatory diseases. For the identification of these molecular targets, animal venoms, …
Work to be developed: the professional to be hired will have as main activities the analysis of digitalized results of the atomic experiments developed in CENTD, especially transcriptomics and proteomics. It should collaborate in the analysis and proposals of the most significant pathways and genes, besides looking for correlations with drugs and diseases. Finally, it should propose new e…
(Only some records are available in English at this moment)
Senescent cells accumulate in many vertebrate tissues with age and contribute to many age-related diseases. Age is a risk factor for osteoarthritis, a chronic condition characterized by articular cartilage degeneration that causes pain and physical disability. Senescent chondrocytes are a possible therapeutic target for treating degenerative diseases and are susceptible to senomorphic dru…
Animal toxins, derived from snakes, spiders, insects and snails of the genus Conus, are remarkable collection of molecules with a pharmaceutical potential. These toxins represent a great diversity of functions and are involved in the evolution of several natural process. They interact, with high affinity and selectivity, with molecular targets that play critical physiological roles. Due t…
| 6 / 6 | Ongoing research grants |
| 20 / 8 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 52 / 19 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 1 / 1 | Completed scholarships abroad |
| 83 / 38 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID